ストックスクリーナーアプリを入手
150.97
0.81%
-1.24
アフターアワーズ：
151.50
0.53
+0.35%
前日終値:
$152.21
開ける：
$152.36
24時間の取引高:
1.33M
Relative Volume:
0.85
時価総額：
$22.13B
収益：
$9.61B
当期純損益:
$1.53B
株価収益率:
14.44
EPS:
10.453
ネットキャッシュフロー:
$1.85B
1週間 パフォーマンス:
-2.11%
1か月 パフォーマンス:
+6.81%
6か月 パフォーマンス:
+32.37%
1年 パフォーマンス:
-17.19%
1日の値動き範囲:
$149.64
$152.36
1週間の範囲:
$149.64
$160.20
52週間の値動き範囲:
$110.03
$194.13
Biogen Inc Stock (BIIB) Company Profile
BIIB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIIB
Biogen Inc
|
150.97 | 22.32B | 9.61B | 1.53B | 1.85B | 10.45 |
|
LLY
Lilly Eli Co
|
845.72 | 756.28B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
189.69 | 454.91B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.24 | 411.31B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
132.31 | 254.66B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
86.40 | 218.83B | 63.43B | 16.42B | 14.72B | 6.4861 |
Biogen Inc Stock (BIIB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-25 | 開始されました | Jefferies | Buy |
| 2025-07-21 | 再開されました | Truist | Hold |
| 2025-04-28 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-04-04 | ダウングレード | Argus | Buy → Hold |
| 2025-02-11 | 開始されました | Bernstein | Mkt Perform |
| 2025-01-02 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-12-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-16 | ダウングレード | Stifel | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-11-18 | ダウングレード | Needham | Buy → Hold |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-31 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-14 | 繰り返されました | Needham | Buy |
| 2024-02-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-01-24 | ダウングレード | UBS | Buy → Neutral |
| 2023-12-20 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-12-07 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-24 | 繰り返されました | UBS | Buy |
| 2023-05-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-04-17 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-26 | アップグレード | Goldman | Neutral → Buy |
| 2022-10-13 | アップグレード | Stifel | Hold → Buy |
| 2022-10-07 | アップグレード | Argus | Hold → Buy |
| 2022-09-28 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2022-09-28 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-28 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-04-18 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-02-04 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-04 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-04 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-04 | 繰り返されました | Cowen | Outperform |
| 2022-02-04 | 繰り返されました | Morgan Stanley | Overweight |
| 2022-02-04 | 繰り返されました | Needham | Buy |
| 2022-02-04 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-04 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2022-02-04 | 繰り返されました | Robert W. Baird | Neutral |
| 2022-02-04 | 繰り返されました | Wedbush | Neutral |
| 2022-02-04 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-02-04 | 繰り返されました | Wolfe Research | Peer Perform |
| 2022-01-13 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-01-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-12-10 | 再開されました | Raymond James | Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-09-23 | 開始されました | Needham | Buy |
| 2021-06-18 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-06-14 | 繰り返されました | Truist | Buy |
| 2021-06-11 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-06-10 | アップグレード | UBS | Neutral → Buy |
| 2021-06-08 | アップグレード | Atlantic Equities | Underweight → Neutral |
| 2021-06-08 | 繰り返されました | Barclays | Equal Weight |
| 2021-06-08 | アップグレード | Citigroup | Sell → Neutral |
| 2021-06-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-06-08 | 繰り返されました | Jefferies | Buy |
| 2021-06-08 | 繰り返されました | Morgan Stanley | Overweight |
| 2021-06-08 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2021-06-08 | アップグレード | Robert W. Baird | Underperform → Neutral |
| 2021-06-08 | 繰り返されました | Stifel | Buy |
| 2021-06-08 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2021-06-07 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-06-07 | アップグレード | Cowen | Market Perform → Outperform |
| 2021-06-07 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2021-02-05 | ダウングレード | DZ Bank | Buy → Hold |
| 2021-01-29 | アップグレード | Stifel | Hold → Buy |
| 2020-11-10 | アップグレード | DZ Bank | Hold → Buy |
| 2020-11-09 | ダウングレード | Atlantic Equities | Neutral → Underweight |
| 2020-11-09 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-11-09 | ダウングレード | Cowen | Outperform → Market Perform |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-04 | アップグレード | BofA Securities | Underperform → Neutral |
| 2020-11-04 | アップグレード | Jefferies | Hold → Buy |
| 2020-11-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-07-27 | アップグレード | Morgan Stanley | Underweight → Overweight |
| 2020-06-22 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2020-06-22 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2020-06-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-04-23 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-04-23 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-01-27 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-12-13 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2019-12-02 | ダウングレード | Robert W. Baird | Neutral → Underperform |
すべてを表示
Biogen Inc (BIIB) 最新ニュース
Biogen stock price target lowered to $217 from $219 at RBC Capital - Investing.com UK
Royal Bank Of Canada Lowers Biogen (NASDAQ:BIIB) Price Target to $217.00 - MarketBeat
Central Nervous System Biomarkers Market Growth & Industry - openPR.com
Leerink Partnrs Issues Negative Forecast for Biogen Earnings - MarketBeat
Biogen Inc. $BIIB Shares Purchased by KLP Kapitalforvaltning AS - MarketBeat
Ascent Group LLC Takes $341,000 Position in Biogen Inc. $BIIB - MarketBeat
Biotechnology Market Therapeutic Innovations & Forecast Report 2025-2033 Featuring Lonza, Amgen, Syn - PharmiWeb.com
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation - GuruFocus
Neuromuscular Disease Therapeutics Market to Reach US$ 45.62 Billion by 2033 as Gene Therapies and RNA-based Treatments Redefine Patient Outcomes - Yahoo Finance
Bioarctic's Leqembi Maintenance Therapy Launched in the United States - MarketScreener
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug - GuruFocus
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S. - GuruFocus
Leqembi Iqlik subcutaneous injection now available in US By Investing.com - Investing.com Australia
Biogen Inc. stock underperforms Monday when compared to competitors - MSN
Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S. - GuruFocus
Leqembi Iqlik subcutaneous injection now available in US - Investing.com
Eisai and Biogen Launch LEQEMBI Companion™ Program to Enhance Resources for Alzheimer's Disease Treatment - Quiver Quantitative
Biogen told to pay $124M in patent dispute with Genentech - Fierce Pharma
Rothschild & Co Redburn Increases Biogen (NASDAQ:BIIB) Price Target to $150.00 - MarketBeat
Rothschild & Co Redburn Adjusts Price Target on Biogen to $150 From $149, Maintains Neutral Rating - MarketScreener
In Vitro Monoclonal Antibodies Market to hit US$ 8.4 Billion - openPR.com
Acetylcholinesterase Inhibitors Market to hit US$ 9.03 Billion - openPR.com
Can Biogen Inc. stock double in next 5 yearsJuly 2025 Fed Impact & Long-Term Safe Investment Ideas - newser.com
Grimes & Company Inc. Sells 18,310 Shares of Biogen Inc. $BIIB - MarketBeat
J. Safra Sarasin Holding AG Sells 7,635 Shares of Biogen Inc. $BIIB - MarketBeat
Mirae Asset Global Investments Co. Ltd. Raises Holdings in Biogen Inc. $BIIB - MarketBeat
Is Biogen Inc. stock a defensive play in 2025Oil Prices & Verified Swing Trading Watchlist - newser.com
A Look at Biogen (BIIB) Valuation Following Australian LEQEMBI Approval and Fresh Analyst Optimism - simplywall.st
Biogen Idec : Biogen Idec Named Top Employer by Science Magazine - MarketScreener
Day 6 of Gains Streak for Biogen Stock with 18% Return (vs. 4.6% YTD) [10/3/2025] - Trefis
Biogen Inc. (BIIB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Biogen (BIIB) Gains as LEQEMBI Wins Australian Approval for Early Alzheimer’s Treatment - simplywall.st
[Updated 2026] Biotechnology Market Size & Sector Scope 2032 - openPR.com
Jefferies Initiates Coverage on Biogen Inc. (BIIB) with Buy Rating and $190 PT - MSN
Biogen must pay $88 million more for use of infamous Cabilly patent - IAM Patent
Could Eisai Partnership and New LEQEMBI Approval Reshape Biogen's (BIIB) Alzheimer's Strategy? - simplywall.st
United States SMN1 Gene Replacement Market is expected to reach - openPR.com
Is Global Expansion of LEQEMBI Enough to Reinforce Biogen’s (BIIB) Long-Term Pipeline Strength? - Yahoo Finance
Biogen Inc. $BIIB Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
Greenleaf Trust Raises Holdings in Biogen Inc. $BIIB - MarketBeat
6 Healthcare Stocks Positioned to Soar After Trump-Pfizer Deal - Investing.com
Biogen’s Global Expansion and Promising Data Fuel Alzheimer’s Treatment Optimism - AD HOC NEWS
Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns - FinancialContent
Biogen owes Genentech $88 million in MS drug dispute, US judge says - Reuters
Biogen Inc. stock outperforms competitors on strong trading day - MarketWatch
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years - Benzinga
Biogen’s Bold Moves: Navigating the Market Waves - StocksToTrade
Biogen (NASDAQ:BIIB) Trading 8.1% HigherStill a Buy? - MarketBeat
Biogen Receives Regulatory Approvals: Stock to Surge? - timothysykes.com
Biogen Inc (BIIB)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Amgen and Biogen settle patent dispute over Prolia and Xgeva biosimilars - Seeking Alpha
Biogen Inc (BIIB) 財務データ
収益
当期純利益
現金流量
EPS
Biogen Inc (BIIB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Singhal Priya | Head of Development |
Aug 29 '25 |
Option Exercise |
0.00 |
1,669 |
0 |
7,096 |
| Singhal Priya | Head of Development |
Sep 02 '25 |
Sale |
133.55 |
517 |
69,045 |
5,772 |
0.80%
1.26%
大文字化:
|
ボリューム (24 時間):